Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Terminated

Conditions: Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Stage III Non-Small Cell Lung Cancer AJCC v7
Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions: Procedure: Biospecimen Collection
Other: Laboratory Biomarker Analysis

Brief Summary: This pilot research trial studies the collection of blood samples in monitoring tumor specific mutations in patients with non-small cell lung cancer that has spread to other places in the body or cannot be removed by surgery. Collecting blood samples may help measure the changes in lung cancer, better learn methods to track cancer in the bloodstream, and improve cancer treatments.

Detailed Description: PRIMARY OBJECTIVES:

I. To evaluate the ability of next generation sequencing (NGS) to monitor the evolution of cancer-specific mutations in patients undergoing treatment for non-small cell lung carcinoma and for whom the molecular profile of the tumor cells prior to treatment is known.

II. Compare the sensitivity of digital droplet polymerase chain reaction (ddPCR) to that of NGS for detecting the appearance of EGFR T790M mutations in patients treated with an EGFR tyrosine kinase inhibitor.

OUTLINE:

Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.

Recruitment & Eligibility

Inclusion Criteria

A diagnosis of non-small cell lung carcinoma for which the molecular profile of the primary tumor has been obtained from a block of paraffin-embedded, formalin-fixed tissue that remains available
Zubrod performance status 0 or 1
Patients must have metastatic or unresectable disease and be starting a new line of systemic treatment at the time of enrollment; there are no constraints regarding the time interval between the initial collection of samples for molecular profiling studies at the time of diagnosis prior to treatment and subsequent collections of circulating cell-free deoxyribonucleic acid (DNA) or circulating tumor cells
Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Ability to understand and the willingness to sign a written informed consent; Note: There will be no discrimination between type of treatment or whether they are on continuous versus intermittent therapy

Exclusion Criteria

Known severe anemia (hemoglobin [Hb] < 8g/dL)
Patients will be excluded if trackable driver mutations are not identified in the primary tumor tissue

Arm && Interventions

Group	Intervention	Description
Ancillary-Correlative (biospecimen collection)	Biospecimen Collection	Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.
Ancillary-Correlative (biospecimen collection)	Laboratory Biomarker Analysis	Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.

Primary Outcome Measures

Name	Time	Method
Blood sample collection for tumor specific mutations study from patients with non-small cell lung cancer	Baseline to 3 years	Blood samples collected will be used to evaluate the ability of next generation sequencing (NGS) to monitor the evolution of cancer-specific mutations in patients undergoing treatment for non-small cell lung carcinoma and for whom the molecular profile of the tumor cells prior to treatment is known.

Secondary Outcome Measures

Name	Time	Method

Locations (1): USC / Norris Comprehensive Cancer Center
🇺🇸
Los Angeles, California, United States

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial